Next-Generation GLUT Inhibitors: Lactone to Lactam Conversion in Rapaglutin A Confers Resistance to Plasma Esterases

新一代 GLUT 抑制剂:雷帕格鲁汀 A 中内酯向内酰胺的转化赋予其对血浆酯酶的抵抗力

阅读:1

Abstract

Rapaglutin A (RgA) is a potent pan-class I glucose transporter (GLUT) inhibitor identified from the rapafucin library. However, its development is hindered by plasma instability due to the rapid hydrolysis of lactone moieties by carboxylesterases, especially in rodents. To improve its stability, we designed and synthesized RgA analogues in which the lactones were substituted with more stable lactams. We found that substitution of either lactone-enhanced plasma stability, while dual lactam replacement produced the greatest improvement in mouse plasma, which has a high esterase activity. Importantly, the lactam analogues retained most of the inhibitory activity of the parent RgA against GLUT in DLD1 cells. This approach offers a promising strategy to enhance the plasma stability of RgA without significantly compromising its activity, with potential applicability across the rapafucin class of macrocycles.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。